UK-based Compass Pathways Plc has reported positive Phase 3 data for a synthetic psilocybin, and the first classic psychedelic for potential use in treatment-resistant depression. The small molecule drug, COMP360, achieved a clinically meaningful reduction in symptom severity compared with a placebo as measured on the Montgomery-Åsberg Depression Rating Scale, according to the company.
A new stem cell therapy has been recommended for conditional approval by the European Medicines Agency for patients with a blood cancer who need a transplant following chemotherapy and/or radiotherapy but have no suitable donors. The allogeneic product, Zemcelpro, is derived from umbilical cord blood and contains two components. These are expanded CD34+ cells and unexpanded CD34- cells, each derived from the same cord blood unit.
A small molecule drug that has shown benefits for patients with a type of non-alcoholic liver disease is being recommended for a conditional approval in Europe following a similar decision in 2024 by the US Food and Drug Administration. The drug, resmetirom, works by activating the thyroid hormone receptor-beta which is expressed in the liver, kidneys and pituitary gland and regulates metabolic activity. Reduced levels of thyroid hormones, particularly associated with a reduced activity of the receptor, can lead to a build-up of fat in the liver.
Research Strategy
The therapeutic potential of virus-like particles
By John Foerster
Cell and Gene Therapy
Engineering immune cell therapies;
will in vivo approaches work?
By Tim Farries
Interview
Lundbeck to test AI for treating brain disorders
Regulation and Policy
Pharmacovigilance at a crossroads
By Ravi Patel and Anna Melin
Science and Policy
First successful in vivo base editing
By Rosie Bannister
Lundbeck to test AI for treating brain disorders
(109.96 KB)
